Journal
HAEMATOLOGICA
Volume 101, Issue 5, Pages 521-530Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2015.132860
Keywords
-
Categories
Funding
- National Institutes of Health, Bethesda, MD, USA [CA078902, CA018029, CA015704, HL122173]
Ask authors/readers for more resources
Most hematological malignancies occur in older patients. Until recently these patients and those with comorbidities were not candidates for treatment with allogeneic hematopoietic transplantation because they were unable to tolerate the heretofore used high-dose conditioning regimens. The finding that many of the cures achieved with allogeneic hematopoietic transplantation were due to graft-versus-tumor effects led to the development of less toxic and well-tolerated reduced intensity and nonmyeloablative regimens. These regimens enabled allogeneic engraftment, thereby setting the stage for graft-versus-tumor effects. This review summarizes the encouraging early results seen with the new regimens and discusses the two hurdles that need to be overcome for achieving even greater success, disease relapse and graft-versus-host disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available